jRCT1071210120进行中（未招募）不适用
An ancillary study of 'Investigation of efficacy of nivolumab in patients with recurrent and refractory peripheral T cell lymphoma: Investigator initiated phase 2 clinical trial' (W-JHS NHL02-A)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 20
- 主要终点
- Gene and protein expression
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients enrolled in W-JHS NHL02 study (jRCT2071210101)
- •Patients providing the written informed consent.
- •Patients whose specimens for any test in 'biomarker exploration' can be submitted
排除标准
- •Nothing particular
结局指标
主要结局
Gene and protein expression
Gene and protein expression analysis
Gene mutation
Gene mutation analysis
Lymphocyte subset analysis
Lymphocyte subset analysis
Serum cytokine and chemokine
Serum cytokine and chemokine analysis
HLA gene
HLA gene analysis
Single cell analysis
Single cell analysis
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
NEJ062 (TRITON study)Non-Small Cell Lung CancerjRCTs06124001933
已完成
不适用
Lucent-J Study (Lucent-J Study)jRCTs05122001640
进行中（未招募）
不适用
TLG-001J LT Study (TLG-001J LT Study)MyopiajRCTs03223066515
已完成
不适用
Post-trial observational study for a phase II study of accelerator-BNCT for head and neck cancer (JHN002): JHN002 Look Up Studynresectable locally recurrent head and neck squamous cell carcinoma Unresectable head and neck non-squamous cell carcinomaJPRN-UMIN000040501Southern Tohoku BNCT Research Center21
尚未招募
不适用
HIT study (HIT study)jRCT1030250124JCR Pharmaceuticals Co., Ltd.30